Skip to content

Pentoxifylline for sepsis in newborns

Pentoxifylline as adjunctive therapy in sepsis in preterm neonates: A double- blinded randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048665
Enrollment
150
Registered
2023-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P368- Other bacterial sepsis of newborn

Interventions

Intervention1: Pentoxifylline: Neonates in the intervention group will receive Pentoxifylline at a dose of 5mg/kg/hour over 6 hours for 5 consecutive days. Control Intervention1: Placebo: Neonates in

Sponsors

Dr Deepak Chawla
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. New onset of at least two of the following signs after 12 hours of birth AND decision of the clinical care team to start or upgrade antibiotics: -Temperature instability (hypothermia [ 38°C], core- periphery temperature difference >2°C) -Respiratory signs (tachypnea, grunting, intercostal/ subcostal retractions, apnea, cyanosis) -Gastrointestinal signs (feeding intolerance, abdominal distension, altered aspirates, radiological signs) -Neurologic signs (encephalopathy, hypotonia, lethargy, seizures) -Unexplained metabolic acidosis (BE > -10) -Hypoglycemia ( 140 mg/dl) – Increased oxygen requirement or ventilatory support OR 2. Any one of the following AND decision of the clinical care team to start or upgrade antibiotics: -Sclerema -Shock needing inotropic support -Positive blood or CSF culture

Exclusion criteria

Exclusion criteria: Neonates with any of the following conditions will be excluded • IVH (grade 3 or 4) • Major congenital malformation

Design outcomes

Primary

MeasureTime frame
The survival of the neonate with an nSOFA score of 0Timepoint: 7th day of enrolment

Secondary

MeasureTime frame
Adverse outcomes directly attributable to Pentoxifylline (thrombocytopenia [1 lac/cumm], increased gastric residue, vomiting, cholestatic jaundice requiring therapy)Timepoint: During intervention;All cause mortalityTimepoint: Till hospital stay A sensitivity analysis will be done excluding the first 24 hour after enrolment;Duration and type of antibiotics therapyTimepoint: During the episode of sepsis and during hospital stay;Duration and types of inotropic supportTimepoint: During the episode of sepsis and during hospital stay;Duration of assisted ventilation (invasive and non invasive)Timepoint: Till hospital stay;Duration of hospital stayTimepoint: Till discharge from hospital;Need to upgrade antibioticsTimepoint: Till hospital stay;nSOFA score and it’s componentsTimepoint: At 7, 10 and 14 days of enrolment

Countries

India

Contacts

Public ContactDr Deepak Chawla

Government medical college and hospital

drdeepak@gmch.gov.in9646121559

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026